Éric Charpentier
Impact in
- Hematology top 2%
- Multiple Myeloma Research and Treatments
- Oncology top 5%
- Peptidase Inhibition and Analysis
- PARP inhibition in cancer therapy
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
Papers in
- Hematology 11
- Multiple Myeloma Research and Treatments 10
- Oncology 10
- Cancer Treatment and Pharmacology 4
- PARP inhibition in cancer therapy 4
- Peptidase Inhibition and Analysis 4
- Co-authors
- Michael Danso (2 shared papers)Denise A. Yardley (2 shared papers)Eric P. Winer (2 shared papers)Ravi Vij (7 shared papers)Nikoletta Lendvai (7 shared papers)Joseph Mıkhael (5 shared papers)Don M. Benson (4 shared papers)Thomas G. Martin (3 shared papers)
- Journals
- Journal of Clinical Oncology (7 papers)Blood (4 papers)Frontiers in Immunology (2 papers)European Journal of Human Genetics (1 paper)Breast Cancer Research and Treatment (1 paper)
- Partner nations
- United StatesFranceSpain
In The Last Decade
Éric Charpentier
22 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 78
- Hematology 372
- Oncology 652
- Cancer Research 178
- Physiology 45
- Immunology 186
Countries citing papers authored by Éric Charpentier
This map shows the geographic impact of Éric Charpentier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Charpentier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Charpentier more than expected).
Fields of papers citing papers by Éric Charpentier
This network shows the impact of papers produced by Éric Charpentier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Charpentier. The network helps show where Éric Charpentier may publish in the future.
Co-authors
The 25 scholars most cited alongside Éric Charpentier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 229 | |
| 2 | 2011 | 192 | |
| 3 | 2017 | 134 | |
| 4 | 2019 | 70 | |
| 5 | 2018 | 55 | |
| 6 | 2014 | 44 | |
| 7 | 2017 | 37 | |
| 8 | 2020 | 37 | |
| 9 | 2014 | 32 | |
| 10 | 2015 | 29 | |
| 11 | 2016 | 29 | |
| 12 | 2015 | 26 | |
| 13 | 2014 | 23 | |
| 14 | 2017 | 19 | |
| 15 | 2014 | 16 | |
| 16 | 2016 | 14 | |
| 17 | 2019 | 12 | |
| 18 | 2016 | 9 | |
| 19 | 2012 | 7 | |
| 20 | 2019 | 7 |
About Éric Charpentier
Éric Charpentier is a scholar working on Hematology, Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Genetics, having authored 22 papers that have together received 1.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (10 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Cancer Treatment and Pharmacology (4 papers), Chronic Lymphocytic Leukemia Research (4 papers), PARP inhibition in cancer therapy (4 papers), Peptidase Inhibition and Analysis (4 papers), T-cell and B-cell Immunology (3 papers) and Immune Cell Function and Interaction (3 papers). The work is most often cited by research in Hematology (372 citations), Oncology (652 citations), Cancer Research (178 citations), Physiology (45 citations) and Immunology (186 citations). Éric Charpentier has collaborated with scholars based in United States, France and Spain. Frequent co-authors include Michael Danso, Denise A. Yardley, Eric P. Winer, Ravi Vij, Nikoletta Lendvai, Joseph Mıkhael, Don M. Benson, Thomas G. Martin, Rachid Baz and Karl Hsu. Their work appears in journals such as Journal of Clinical Oncology, Blood, Frontiers in Immunology, European Journal of Human Genetics and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.